"The Report
Programmed Cell Death Protein 1 (CD279 or Systemic Lupus
Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Global
Markets Directs, Programmed Cell Death Protein 1 (CD279 or Systemic
Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1
2016, provides in depth analysis on Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1)
targeted pipeline therapeutics.
The
report provides comprehensive information on the Programmed
Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1),
targeted therapeutics, complete with analysis by indications, stage
of development, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally,
the report provides an overview of key players involved in Programmed
Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus
Susceptibility 2 or PD1) targeted therapeutics development and
features dormant and discontinued projects.
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage.
Download Sample copy of this
Report at : http://www.marketresearchreports.biz/sample/sample/726757
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Programmed Cell Death Protein 1 (CD279 or Systemic Lupus
Erythematosus Susceptibility 2 or PD1)
-
The report reviews Programmed Cell Death Protein 1 (CD279 or Systemic
Lupus Erythematosus Susceptibility 2 or PD1) targeted therapeutics
under development by companies and universities/research institutes
based on information derived from company and industry-specific
sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Programmed Cell Death
Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or
PD1) targeted therapeutics and enlists all their major and minor
projects
-
The report assesses Programmed Cell Death Protein 1 (CD279 or
Systemic Lupus Erythematosus Susceptibility 2 or PD1) targeted
therapeutics based on mechanism of action (MoA), route of
administration (RoA) and molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news and deals related to Programmed Cell
Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility
2 or PD1) targeted therapeutics
Reasons to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Programmed Cell Death Protein 1 (CD279 or Systemic Lupus
Erythematosus Susceptibility 2 or PD1)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding
Programmed Cell Death Protein 1 (CD279 or Systemic Lupus
Erythematosus Susceptibility 2 or PD1) development landscape
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Browse
Latest News at http://www.marketresearchreports.biz/articles
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report
Coverage 7
Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1)
Overview 8
Therapeutics Development 9
Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) -
Products under Development by Stage of Development 9
Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) -
Products under Development by Therapy Area 10
Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) -
Products under Development by Indication 11
Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) -
Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) -
Products under Development by Companies 17
Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) -
Products under Development by Universities/Institutes 31
Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) -
Therapeutics Assessment 33
Assessment by
Monotherapy/Combination Products 33
Assessment by Mechanism of
Action 34
Assessment by Route of
Administration 36
Assessment by Molecule Type 38
Programmed Cell Death Protein 1
(CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) -
Companies Involved in Therapeutics Development 40
Agenus, Inc. 40
Aurigene Discovery Technologies
Limited 41
BeiGene, Ltd. 42
Cellular Biomedicine Group,
Inc. 43
CytomX Therapeutics, Inc. 44
Enumeral Biomedical Holdings,
Inc. 45
GlaxoSmithKline Plc 46
Globavir Biosciences, Inc. 47
Immunovo BV 48
Jiangsu Hengrui Medicine Co.,
Ltd. 49
Jounce Therapeutics, Inc. 50
MacroGenics, Inc. 51
MedImmune, LLC 52
Merck & Co., Inc. 53
Merus B.V. 55
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment